Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure: A Necessary Shift

The legacy of general health and science information has long provided a foundational understanding of how pharmaceutical interventions interact with human physiology. Within this broad context, public discourse has historically centered on therapeutic benefits and standard risk profiles, often framed for a general audience. As the domain of mass production evolves, however, the focus must shift from population-level health communication to the specific, measurable exposures encountered in occupational settings. This transition is particularly relevant when examining the relationship between bisphosphonate medications, such as Fosamax, and the risk of osteonecrosis of the jaw. While general health narratives may address patient-side considerations, the occupational exposure concern arises from the manufacturing, handling, and distribution processes inherent in mass production. Workers in pharmaceutical plants, logistics hubs, and related industrial environments may face repeated contact with active pharmaceutical ingredients or intermediates. This pivot from a general health context to an occupational exposure framework requires a rigorous assessment of workplace safety protocols, permissible exposure limits, and longitudinal health monitoring. The following analysis will therefore examine Fosamax exposure specifically within the context of occupational risk, moving beyond patient-centric discussions to address the distinct challenges faced by the workforce involved in its mass production.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation typically involves pain, swelling, and exposed bone in the jaw, which can lead to significant morbidity. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors for ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and metabolic properties of the jawbone that may predispose it to ONJ under antiresorptive therapy. Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Exposure and Evidence from Studies

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the medication, though a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). It also advises that discontinuation of bisphosphonate treatment may reduce risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Clinical Implications

For causation-related considerations, affected patients should be aware that ONJ is a rare but serious adverse effect of Fosamax, with risk increasing with longer exposure. The condition is often triggered by dental procedures or local infection, and symptoms can appear within days to months of starting the drug. Discontinuation of Fosamax may lead to symptom relief, but recurrence can occur with rechallenge. Patients with risk factors such as cancer, corticosteroid use, or poor oral hygiene should be monitored closely. The evidence supports a causal link between bisphosphonate use and ONJ, though the absolute risk remains low in osteoporosis patients.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate used for osteoporosis, has been reported to cause ONJ as a rare but serious adverse effect. The risk increases with longer duration of use and is higher in patients with additional risk factors such as cancer, corticosteroid use, or poor oral hygiene. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What do studies show about the risk of ONJ from Fosamax?

Studies show that the absolute risk of ONJ in osteoporosis patients taking Fosamax is low, approximately 0.05% after 5 years. However, a cohort study found that the risk is threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared to past use. The risk diminishes after discontinuation. Symptoms can appear within days to months of starting the drug, and most patients improve after stopping. (https://pubmed.ncbi.nlm.nih.gov/39400702/)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of Fosamax use also increases risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.